BGB-A317-303
Completed
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
BeOne Study ID
BGB-A317-303
ClinicalTrials.gov ID
EudraCT or EUCT Number
2018-000245-39
China Drug Trials ID
CTR20171112
Study Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No
Study Documents
Study Protocol Statistical Analysis Plan Plain Language SummaryStudy Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No